4-ARCI CONTROLLED THERAPEUTIC MEDICATION SCHEDULE FOR HORSES (1).pdf

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 4.2.1

Revised – December, 2020

Controlled Therapeutic

Medication

Threshold

Withdrawal

Guideline

Dosing Specifications

Reference Notes

Note

Acepromazine

10 nanograms per milliliter as 2-(1-hydroxyethyl) promazine sulfoxide (HEPS) in urine

48 hours

Single intravenous dose of acepromazine at 0.05 milligrams per kilogram

University of California at Davis project

Applicable analyte is metabolite HEPS

Albuterol

1 nanogram per milliliter of urine1

72 hours

720 micrograms total dose intra-nasal only2. Based upon dosing up to 4 times per day

European Horseracing Scientific Liaison Committee Data

See Endnote

Betamethasone

Harness Racing Only.

10 picograms per milliliter of plasma or serum

SEE NOTE

BELOW

7 days

Intra-articular administration of 9 milligrams of Betamethasone

Sodium Phosphate and Betamethasone Acetate

Injectable Suspension, USP (American Regent product

#0517-0720-01)3

RMTC study

Intra-articular dosing only - applicable analyte is betamethasone in plasma or serum

Butorphanol

300 nanograms per milliliter of total butorphanol in urine or 2 nanograms of free butorphanol per milliliter per milliliter of

Single intravenous dose of butorphanol as Torbugesic® (butorphanol tartrate) at 0.1

Journal of Veterinary Pharmacology and Therapeutics doi:

10.1111/j.1365-

2885.2012.01385.x

Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate)

1 For Quarter Horses: Level of Detection in any permitted biological sample.

2 Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol.

3 Intramuscular administration of betamethasone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

ARCI Controlled Therapeutic Medications Schedule Ver. 4.2.1, December 2020

ARCI Controlled Therapeutic Medications Schedule Ver. 4.2, December 2020

Cetirizine

6 nanograms per serum

0.4 milligrams per kilogram twice daily for 5 doses

Kentucky Equine Drug

Research Council/University of

California at Davis study

Do not administer ivermectin within 48 hours of a race if the horse has been administered cetirizine.

Cimetidine

400 nanograms per

24 hours

20 milligrams per kilogram twice daily for 7 doses

Kentucky Equine Drug Research

Council/University of California at Davis study

Clenbuterol (Prohibited in Quarter Horse and Thoroughbred Race Horses)

140 picograms per milliliter of urine or Level of Detection in plasma or serum4

Flat Racing -28 days Harness 14 days5

Oral administration of clenbuterol as Ventipulmin® syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140-

973) at 0.8 mcg/kg twice a day at Davis;

Boehringer-Ingelheim

Vetmedica, Inc.

clenbuterol

Dantrolene

100 picograms per milliliter of

5-hydroxydantrolene in

Oral administration of 500 milligrams of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble)

Therapeutics 34, 238–

Detomidine

2 nanograms per milliliter of carboxydetomidine in urine or 1 nanogram per milliter of detomidine in blood.

5 mg IV (once)

KY EDRC, UC

Davis/UF Study.

Dormosedan ™ used in study.

4 For Quarter Horses or Thoroughbreds: Level of Detection in any permitted biological sample.

5 Clenbuterol is a prohibited substance in Quarter Horses and other breeds racing with Quarter Horses; there is no applicable withdrawal guideline for such horses.

Dexamethasone

5 picograms per milliliter of plasma or serum

Intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone at

0.05milligrams per kilogram regardless of route

RMTC study dexamethasone in

Dimethyl sulfoxide

(DMSO)

10 micrograms per

Intravenous

ARCI model rule

DMSO in plasma or

Furosemide

100 nanogram per

4 hours

Single Intravenous dose of furosemide up to 500 milligram6

ARCI model rule

Must also have urine specific gravity <

1.010 for a violation.

Glycopyrrolate

3 picograms per milliliter

Single intravenous dose of 1 milligram of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product #

0517-4601-25)

RMTC study; Journal of Veterinary Pharmacology and Therapeutics doi:

10.1111/j.1365-

2885.2011.01272.x glycopyrrolate in

6 ARCI-0110929(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide “shall not exceed 500 milligrams nor be less than 150 milligrams.”

Guaifenesin

12 nanograms per

2 grams twice daily for 5 doses

Council/University of

Isoflupredone serum

10 milligrams total dose subcutaneous or 20 milligrams total dose in one articular space

RMTC Study

Lidocaine

20 picograms per milliliter of total 30H-lidocaine in plasma or

200 milligrams of lidocaine as its hydrochloride salt administered subcutaneously

European Horseracing

Committee data; Iowa State University study.

Applies to total major hydroxylated metabolite (i.e., includes conjugates)

Mepivacaine

10 nanograms total hydroxymepivacaine per milliliter of urine or above Level of Detection of mepivacaine in plasma or serum

Single 0.07 milligrams per kilogram subcutaneous dose of mepivacaine

European Horseracing

Committee data

Methocarbamol

Single intravenous dose of 15 methocarbamol as Robaxin® or

5 grams orally

Therapeutics doi:

10.1111/jvp.12068 methocarbamol in

Methylprednisolone

See Dosing Specifications

Total dose of methylprednisolone acetate suspension in one articular space7. The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100 milligram dose

Therapeutics volume 37, Issue 2, pages 125–132, April methylprednisolone

Omeprazole omeprazole sulfide -

10 nanograms per

Orally (2.2 grams) once daily for 4 doses

Kentucky Equine Drug Research

Council/University of

GastroGuard™ used in the study

Prednisolone

1 milligram per kilogram orally prednisolone in plasma or serum

Procaine penicillin

(administration must be reported to Commission)

25 nanograms per

Following entry to race

Intramuscular

RMTC – reference notes online

Mandatory surveillance of horse at owner’s expense 6 hours before racing

7 Intramuscular administration of methylprednisolone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.

Ranitidine

40 nanograms per

8 milligrams per kilogram twice daily for 7 doses

Council/University of

Triamcinolone acetonide

Harness Racing Only serum

Total dose of 9 milligram in one articular space8

Equine Veterinary Journal, 10.1111/evj.12059 (2013) triamcinolone acetonide in plasma or serum

Xylazine

200 picograms per

200 milligrams intravenously at Davis study xylazine.

NOTE: The thresholds and withdrawal guidance for corticosteroids other than methylprednisolone do not apply to flat and jump racing which have a mandatory stand down period of 14 days following intra-articular injections and a prohibition on stacking pursuant to ARCI 011-020(F).

8 Intramuscular administration of triamcinolone acetonide will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

Non-Steroidal Anti-Inflammatory Drug (NSAID) Rules for Horses††

Threshold (Primary)

Restricted Administration

Time

Flunixin

5.0 nanogram per

Single intravenous dose of flunixin as Banamine® (flunixin meglumine) at

1.1 milligram per kilogram

University of California at Davis/RMTC

Ketoprofen

2.0 nanograms per

Single intravenous dose of ketoprofen as

Ketofen® at 2.2 milligrams per

HFL Sport Sciences/ Kentucky Equine Drug and Research Council/RMTC study/University of California Davis/RMTC.

Phenylbutazone

0.3 micrograms per

Single intravenous dose of phenylbutazone at

4.0 milligrams per

University of California Davis/RMTC study.

†† Samples collected may contain one of the NSAIDs in this chart at a concentration up to the Primary Threshold. The detection of one or more additional NSAIDs in blood and/or urine constitutes a stacking violation in addition to the violation associated with the detection of each additional NSAID.

Recent Document Revisions Date Version Substance Notes.

19-Dec

4.2

Betamethasone, Dexamethasone, Isoflupredone, Prednisolone, Triamcinolone acetonide.

Threshold and withdrawal guidance eliminated for flat and jump races; thresholds and withdrawl times apply only to harness racing. Fourteen day (14) stand down on interarticular injections referenced in Note.

Phenylbutazone Threshold lowered to 0.3 micrograms per milliliter plasma/serum; 48-hour restricted administration time;

Elimination of secondary threshold; Footnote on stacking modified.

Ketoprofen

48-hour restricted administration time; Elimination of secondary threshold; Footnote on stacking modified.

Flunixen Threshold lowered to 5.0 ng/ml; 48-hour restricted administration time; Elimination of secondary threshold; Footnote on stacking modified.

Diclofenac and Firocoxib

Eliminated from CTS schedule; Policy reverts to level of detection if found.

19-Jan

4.1

Albuterol Added footnote establishing Albuterol as a prohibited substance in Quarter Horses with no applicable withdrawal guideline for Quarter Horses or breeds racing with Quarter Horses.

17-Apr 4 Clenbuterol Added footnotes establishing Clenbuterol as a prohibited substance in Quarter Horses with no applicable withdrawal guideline for Quarter Horses or breeds racing with Quarter Horses.

17-Apr 4 Whole document Re-numbered footnotes throughout document to make them continuous

16-Dec 3.2 Omeprazole Clarified threshold for omeprazole sulfide.

16-Sep 3.1 Detomidine Amended threshold and dosing specifications.

16-Mar 3 Omeprazole Amended threshold and dosing specifications

16-Mar 3 Xylazine Amended threshold and dosing specifications

16-Mar 3 Guaifenesin Added as New Substance to Controlled Therapeutic Medication Schedule

16-Mar 3 Cetirizine Added as New Substance to Controlled Therapeutic Medication Schedule

16-Mar 3 Ranitidine Added as New Substance to Controlled Therapeutic Medication Schedule

16-Mar 3 Cimetidine Added as New Substance to Controlled Therapeutic Medication Schedule

15-Apr 2.02 Methylprednisolone Directed readers to use Dosing Specification column for recommended withdrawal guideline.

15 A 2 02 F id Added clarifying language to Furosemide reflecting ARCI-011- 020(F)(2)(d) and ARCI-025-

14-Apr 2.01 Methocarbamol Corrected dosage from 0.15 milligrams per kilogram to 15 milligrams per kilogram

14-Apr 2 Dimethyl sulfoxide (DMSO) Removed “oral” from dosing specifications

14-Apr 2 Xylazine Changed Note section from “Applies to xylazine and xylazine metabolite” to “Applies to analyte xylazine”

Apr-14 2 Isoflupredone Added Isoflupredone as New Substance to Controlled Therapeutic Medication Schedule

Apr-14 2 Albuterol Added Albuterol as New Substance to Controlled Therapeutic Medication Schedule

Apr-14 2 Flunixin, Ketoprofen, Phenylbutazone Added Secondary Anti-Stacking Threshold

Apr-14 2 Flunixin, Ketoprofen, Phenylbutazone Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Controlled Therapeutic Medication Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section

Apr-14 2 <All Substances> Changed Table Header from “No Pre-Race Treatment Within” to “Withdrawal Guideline”

Apr-13 1 <All Substances> Original Controlled Therapeutic Medication Schedule Adopted by ARCI Board of Directors